PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
IPO Year:
Exchange: NYSE
Website: perkinelmer.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2022 | $170.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 12/12/2022 | $135.00 → $170.00 | Neutral → Buy | Citigroup |
| 12/6/2022 | $192.00 → $164.00 | Market Perform → Outperform | Cowen |
| 11/28/2022 | $130.00 → $145.00 | Underweight → Equal Weight | Barclays |
| 8/25/2022 | $175.00 | Neutral | Credit Suisse |
| 8/18/2022 | $190.00 → $170.00 | Buy → Hold | Stifel |
| 8/2/2022 | $178.00 | Buy → Neutral | BofA Securities |
| 7/20/2022 | $160.00 | Buy | UBS |
| 7/5/2022 | $150.00 | Outperform → In-line | Evercore ISI |
| 5/18/2022 | $125.00 | Underweight | Barclays |
8-K - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
11-K/A - REVVITY, INC. (0000031791) (Filer)
11-K - REVVITY, INC. (0000031791) (Filer)
SD - REVVITY, INC. (0000031791) (Filer)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - REVVITY, INC. (0000031791) (Subject)
SC 13G/A - PERKINELMER INC (0000031791) (Subject)
SC 13G/A - PERKINELMER INC (0000031791) (Subject)
SC 13G/A - PERKINELMER INC (0000031791) (Subject)
SC 13G - PERKINELMER INC (0000031791) (Subject)
SC 13G/A - PERKINELMER INC (0000031791) (Subject)
KeyBanc Capital Markets upgraded PerkinElmer from Sector Weight to Overweight and set a new price target of $170.00
Citigroup upgraded PerkinElmer from Neutral to Buy and set a new price target of $170.00 from $135.00 previously
Cowen upgraded PerkinElmer from Market Perform to Outperform and set a new price target of $164.00 from $192.00 previously
Barclays upgraded PerkinElmer from Underweight to Equal Weight and set a new price target of $145.00 from $130.00 previously
Credit Suisse initiated coverage of PerkinElmer with a rating of Neutral and set a new price target of $175.00
Stifel downgraded PerkinElmer from Buy to Hold and set a new price target of $170.00 from $190.00 previously
BofA Securities downgraded PerkinElmer from Buy to Neutral and set a new price target of $178.00
UBS initiated coverage of PerkinElmer with a rating of Buy and set a new price target of $160.00
Evercore ISI downgraded PerkinElmer from Outperform to In-line and set a new price target of $150.00
Barclays initiated coverage of PerkinElmer with a rating of Underweight and set a new price target of $125.00
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective the same date but will remain as a consultant to the Company to assist with the transition."I am thrilled to welcome Jamey to Moderna's Executive Committee as our Chief Financial Officer. Moderna is at an exciting stage with a
Max Krakowiak appointed new chief financial officer, replacing Jamey Mock PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity. The Company's Board of Directors has unanimously appointed Max Krakowiak to succeed Mr. Mock as its new senior vice president and CFO, effective as of September 6, 2022. Mr. Krakowiak is currently the Company's vice president of corporate finance, and has served in financial leadership roles of increasing responsibility for the last four years. "I would like to thank Jamey
Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021. PerkinElmer's strong revenue performance was driven by broad-based momentum across the portfolio. In total, non-COVID-19, or core, demand increased approximately 10% organically year-over-year, and COVID-19 related solutions contributed approximately $535 million of revenue in the first quarter. PerkinElmer will release its first quarter 2021 financial results a
CANTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announces the appointment of David C. Francisco as the Company’s Chief Financial Officer, effective February 15, 2021. In connection with the hiring of Mr. Francisco, Henry Hagopian will serve as the Company’s Senior Vice President of Finance and Treasurer. “I am pleased to welcome Dave to the Organogenesis executive leadership team,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Orga
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 66% and 63%, respectively, GAAP earnings per share from continuing operations of at least $2.88, and adjusted earnings per share from continuing operations of at least $3.60 for the fourth quarter ended January 3, 2021. The ongoing strong performance was driven by better-than-expected demand for PerkinElmer’s full-suite of COVID-19 and non-COVID-19 solutions. In total, COVID-19 related offerings contributed approximately $535 million of revenue and the non-COVID-19 port
WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”). Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordina
Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp
Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev
The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon
PerkinElmer Inc. (NYSE:PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 –
CALGARY, AB, March 13, 2023 /PRNewswire/ - Parkland Corporation ("Parkland") (TSX:PKI) announces that a dividend of $0.34 per share will be paid on April 14, 2023 to shareholders of record on March 22, 2023. The dividend will be an 'eligible dividend' for Canadian income tax purposes. The ex-dividend date is March 21, 2023. Forward-Looking Statements Certain statements contained in this news release constitute forward-looking information and statements (collectively, "forward looking statements"). When used in this news release, the words "expect'', ''will'', ''could'', ''woul
Transforms into new Life Sciences and Diagnostics company PerkinElmer Inc. (NYSE:PKI), today announced that it has successfully completed the previously announced divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a growth-oriented investment firm. The resulting new, high-growth Life Sciences and Diagnostics business, focused on developing and delivering novel scientific breakthroughs that will have a profound impact on improving global health, will share the PerkinElmer name with the Applied, Food and Enterprise Services businesses until a new name, brand and ticker symbol is unveiled in Q2 2023 pending shareholder approval. "Today marks the cul
Fourth quarter revenue from continuing operations of $741 million; (28)% reported growth; (23)% organic growth; 8% non-COVID organic growth Combined* total fourth quarter revenue of $1,089 million; 8% combined non-COVID organic growth Fourth quarter GAAP EPS from continuing operations of $0.85; combined adjusted EPS of $1.70 Initiates Full Year 2023 Guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 1, 2023. Fourth Quarter 2022 The Company reported GAAP earnings per share from continuing operations of $0.85, as compared to GAAP earnings per share
The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 12, 2023 to all shareholders of record at the close of business on April 21, 2023. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available at www.perkinelmer.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005743/en/
PerkinElmer Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it will release its fourth quarter and full year 2022 financial results prior to market open on Tuesday, February 14, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. The Company is also updating its fourth quarter 2022 guidance as previously provided on Novembe
Third quarter revenue of $712 million; (17)% reported growth Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth Third quarter GAAP EPS from continuing operations of $0.55; pro forma adjusted EPS of $1.51 Initiates fourth quarter and updates full year pro forma guidance PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 2, 2022. The Company reported GAAP earnings per share from continuing operations of $0.55, as compared to GAAP earnings per share from continuing operations of $0.94 in the same period a year ago. GAAP revenue for the quarter
Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp
Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev
Approximately $2.1 Billion in New Commitments Closed in the First Quarter and Approximately $23.5 Billion closed in the Last Twelve Months Ended March 31, 2023 Ares Management Corporation announced today that funds managed by its Credit Group (collectively "Ares") closed approximately $2.1 billion in U.S. direct lending commitments across 35 transactions during the first quarter of 2023 and approximately $23.5 billion in U.S. direct lending commitments across 189 transactions in the last twelve-month period ended March 31, 2023. Below is a description of selected transactions that Ares closed during the first quarter. Banyan Software Ares served as the agent, lead arranger and bookrun
The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon
PerkinElmer Inc. (NYSE:PKI), today announced that it will release its first quarter 2023 financial results prior to market open on Thursday, May 11, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 –
CALGARY, AB, March 13, 2023 /PRNewswire/ - Parkland Corporation ("Parkland") (TSX:PKI) announces that a dividend of $0.34 per share will be paid on April 14, 2023 to shareholders of record on March 22, 2023. The dividend will be an 'eligible dividend' for Canadian income tax purposes. The ex-dividend date is March 21, 2023. Forward-Looking Statements Certain statements contained in this news release constitute forward-looking information and statements (collectively, "forward looking statements"). When used in this news release, the words "expect'', ''will'', ''could'', ''woul
Transforms into new Life Sciences and Diagnostics company PerkinElmer Inc. (NYSE:PKI), today announced that it has successfully completed the previously announced divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a growth-oriented investment firm. The resulting new, high-growth Life Sciences and Diagnostics business, focused on developing and delivering novel scientific breakthroughs that will have a profound impact on improving global health, will share the PerkinElmer name with the Applied, Food and Enterprise Services businesses until a new name, brand and ticker symbol is unveiled in Q2 2023 pending shareholder approval. "Today marks the cul
PerkinElmer Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023 at 2:15 p.m. ET. Steve Willoughby, senior vice president, investor relations & head of ESG, and Alan Fletcher, senior vice president, Life Sciences, will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company's website at www.perkinelmer.com. A replay of the presentation will be posted on the PerkinElmer Investor Relations website after the e
Company will showcase ultrasensitive platform for high-throughput screening applications at SLAS2023 alongside its newest NGS liquid handler while highlighting other workflow innovations PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched the EnVision® Nexus™ system, its fastest and most sensitive multimode plate reader to date, designed for demanding high-throughput screening (HTS) applications and to accelerate drug discovery efforts. The EnVision Nexus platform, with complementary microplates and optimized reagents from PerkinElmer's drug discovery reagents portfolio, including proprietary HTRF® and AlphaLISA® technologies and lat
PerkinElmer Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Cowen 43rd Annual Health Care Conference and the Barclays Global Healthcare Conference. Cowen 43rd Annual Health Care Conference – Boston, MA Monday, March 6, 2023 9:10 a.m. ET – Max Krakowiak, senior vice president and chief financial officer Barclays Global Healthcare Conference – Miami, FL Tuesday, March 14, 2023 8:00 a.m. ET – Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities. Live audio webcasts will be available on the Events section of the Company's website
Revvity (NYSE:PKI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Revvity has an average price target of $154.5 with a high of $182.00 and a low of $125.00. Below is a summary of how these 6 analysts rated Revvity over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock This c
Citigroup analyst Patrick Donnelly maintains Revvity (NYSE:PKI) with a Buy and lowers the price target from $170 to $160.
Stifel analyst Daniel Arias maintains Revvity (NYSE:PKI) with a Hold and lowers the price target from $145 to $135.
Baird analyst Catherine Schulte maintains Revvity (NYSE:PKI) with a Outperform and lowers the price target from $182 to $165.
Barclays analyst Luke Sergott maintains Revvity (NYSE:PKI) with a Equal-Weight and lowers the price target from $140 to $125.
Revvity, Inc. (NYSE:PKI) reported the first quarter of FY23 revenues of $674.87 million, missing the consensus of $751.04 million. Revenues fell 29.9% year over year. Formerly known as PerkinElmer, the diagnostics and scientific solutions firm reported adjusted earnings per share of $1.01, missing the analyst consensus of $1.06. Weakness in diagnostics revenues and lower margins weighed on the quarterly performance. Segments: Lifesciences revenues rose 7.3% Y/Y to $328.44 million. Diagnostics revenues fell 47.3% to $346.63 million. Adjusted operating profit margin slumped a massive 1,280 basis points to 28%, as compared to 40.8% Y/Y. The company exited the quarter with $2.5 billion
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter. • Addex Therapeutics (NASDAQ:ADXN) is projected to report earnings for its first quarter. • Fiverr Intl (NYSE:FVRR) is expected to report quarterly earnings at $0.24 per share on revenue of $87.66 million. • Teekay (NYSE:TK) is likely to report earnings for its first quarter. • Teekay Tankers (NYSE:TNK) is likely to report quarterly earnings at $4.38 per share on revenue of $243.55 million. • Pharming (NASDAQ:PHAR) is likely to report earnings for its first quarter. • Algonq
Revvity (NYSE:PKI) reported its Q1 earnings results on Thursday, May 11, 2023 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Revvity missed estimated earnings by 4.72%, reporting an EPS of $1.01 versus an estimate of $1.06. Revenue was down $584.13 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.08 which was followed by a 1.91% drop in the share price the next day. Here's a look at Revvity's past performance: Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022 EPS Estimate 1.62 1.45 2.02 2.08 EPS Actual 1.70 1.51 2.32 2.41 Revenue Estimate 1.04B 1.01B 1.20B 1.18B Revenue Actual 1.09B 1.03B 1.23B 1